Composition
Tab: Ticlopidine HCI 250 mg.
Indications & Dosage
Reduction of risk of first and recurrent stroke, Prevention of major ischaemic accidents particularly coronary with chronic arterial diseases of the lower limb at all the stages of intermittent claudication: Adults: 250 mg twice daily. Coronary Artery Scenting: Adult: 250 mg twice daily with Aspirin up to 30 days after stent implant (with food). Children: Not recommended.
Contraindications
Haemorrhagic diathesis, active peptic ulcer, acute haemorrhage, prolonged bleeding, leucopenia, thrombocytopenia agranulocytosis.
Precautions
Impaired liver function; discontinue if hepatitis or jaundice develop. Haematological monitoring and Platelet count should be performed at the start of the treatment followed by every two weeks for the first three months and within 15 days after discontinuation of the therapy.
Interactions
NSAIDs. Antiplatelet drugs, oral anticoagulants, heparins & salicylate derivatives, theophylline, digoxin, phenytoin.
Pregnancy
Caution advised
Lactation
Not recommended.
Side Effects
Neutropenia, bonemarrow aplasia or pancytopenia, thrombotic, thrombocytopenic purpura, throwbocytopenia, haemorrhagic complications may occur, nausea, diarrhoea, cutaneous, skin rashes of maculopapular & urticadet typemay occur within first three months of the therapy, hepatitis and cholestatic jaundice.